Product nameAnti-Fibrinogen beta chain antibody [EPR3082]
See all Fibrinogen beta chain primary antibodies
DescriptionRabbit monoclonal [EPR3082] to Fibrinogen beta chain
Tested applicationsSuitable for: WB, IHC-P, ICCmore details
Unsuitable for: IP
Species reactivityReacts with: Human
Synthetic peptide within Human Fibrinogen beta chain aa 150-250. The exact sequence is proprietary.
- WB: Human prostate and Human plasma lysates IHC-P: Human liver tissue
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab92510 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB: 1/5000 - 1/10000. Predicted molecular weight: 56 kDa.
Is unsuitable for IP.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGB are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This rare autosomal recessive disorder is characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=Patients with congenital fibrinogen abnormalities can manifest different clinical pictures. Some cases are clinically silent, some show a tendency toward bleeding and some show a predisposition for thrombosis with or without bleeding.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsConversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
- Information by UniProt
- Beta fibrinogen antibody
- Epididymis Secretory Sperm Binding Protein Li 78p antibody
- FGB antibody
All lanes : Anti-Fibrinogen beta chain antibody [EPR3082] (ab92510) at 1/5000 dilution
Lane 1 : Human prostate lysate
Lane 2 : Human plasma lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 56 kDa
ab92510, at a 1/50 dilution, staining Fibrinogen beta chain in formalin fixed, paraffin embedded Human liver tissue by Immunohistochemistry. Detection: by DAB staining
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
ab92510 has not yet been referenced specifically in any publications.